Journal article
Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency
Abstract
Engineered T cell therapies have revolutionized modern oncology, however processes for manufacturing T cell therapies vary and the impact of manufacturing processes On the cell product is poorly understood. Herein, we have used a commercially available hollow fiber membrane bioreactor (HFMBR) operated in a novel mode to demonstrate that T cells can be engineered with lentiviruses, grown to very high densities, and washed and harvested in a …
Authors
Yoo SM; Lau VWC; Aarts C; Bojovic B; Steinberg G; Hammill JA; Dvorkin-Gheva A; Ghosh R; Bramson JL
Journal
OncoImmunology, Vol. 10, No. 1,
Publisher
Taylor & Francis
Publication Date
1 2021
DOI
10.1080/2162402x.2021.1995168
ISSN
2162-4011